SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2018, filed its annual 10-K with the Securities and Exchange Commission, and shared recent business highlights. Recent Business […]
Tag: BioCardia
BioCardia Submits 510(k) Application to FDA for AVANCE Steerable Introducer for Transseptal Access to Heart
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced its 510(k) submission for U.S. Food and Drug Administration (FDA) clearance of the AVANCE™ steerable introducer, designed for introducing various cardiovascular catheters into the heart, including via the left side […]
Positive 12-Month Data on BioCardia’s Investigational CardiAMP Cell Therapy System for Heart Failure Presented at American Heart Association Scientific Sessions 2018
CHICAGO & SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive 12 month data for the roll-in cohort of its pivotal CardiAMP™ Heart Failure Trial studying the investigational CardiAMP Cell Therapy System in adult patients experiencing heart failure following a […]
BioCardia Reports Third Quarter 2018 Financial Results and Business Highlights
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the third quarter 2018 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2018 with the […]
BioCardia Welcomes Cardiovascular Device Veteran Mark Schwartz as Vice President of Clinical Affairs
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia® [OTC: BCDA] today announced that Mark Schwartz, a 25-year veteran of cardiovascular device development, has joined the company as Vice President of Clinical Affairs, effective November 1. Schwartz brings extensive leadership experience in the design and execution of clinical studies for medical devices in the heart […]
BioCardia and CellProThera Partner for Clinical Trial and Marketing in Singapore of Early Stem Cell Therapy for Patients Following Myocardial Infarction
SAN CARLOS, Calif. & MULHOUSE, France–(BUSINESS WIRE)–CellProThera® and BioCardia® [OTC: BCDA] today announced an agreement to expand their current collaboration to the SIngXpand Clinical Trial in Singapore. The study will evaluate the safety and efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process and […]
Positive Data On BioCardia’s Investigational CardiAMP Cell Therapy For Heart Failure Presented At Transcatheter Cardiovascular Therapeutics (TCT) Conference
SAN DIEGO and SAN CARLOS, Calif., Sept. 24, 2018 /PRNewswire/ — BioCardia®, Inc. (OTC :BCDA ), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that positive data from two studies of its investigational CardiAMP stem cell therapy were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) conference. CardiAMP cell therapy […]
BioCardia Receives Two New U.S. Patents
SAN CARLOS, Calif., Sept. 14, 2018 /PRNewswire/ — BioCardia®, Inc. [OTC :BCDA ], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of two United Statespatents. U.S. Patent No. 10,035,982 relates to methods of preparing culture-expanded cells for the treatment of heart failure. The patent has broad claims on […]
Preliminary Results From BioCardia’s Phase III Pivotal CardiAMP Heart Failure Trial Reported In Circulation Research Journal
SAN CARLOS, Calif., Aug. 22, 2018 /PRNewswire/ — In a Viewpoint paper published online today in Circulation Research, the Phase III CardiAMP Heart Failure Trial (CardiAMP-HF Trial) studying the investigational CardiAMP stem cell therapyfrom BioCardia®, Inc. (OTC: BCDA) was highlighted as an example of personalized medicine, with promising results from the first 10 patients in the […]
BioCardia, Inc. Reports Second Quarter 2018 Financial Results and Business Highlights
SAN CARLOS, Calif., Aug. 9, 2018 /PRNewswire/ — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second quarter 2018 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2018 with […]
Recent
Popular
- No commented posts yet